Olaris: Russell Herndon, Laura Housman
Metabolomics and machine learning company Olaris has appointed Russell Herndon as its chief business officer and Laura Housman as its chief commercial officer. Herndon was previously CEO of Singapore-based MediSix Therapeutics, a T-cell therapy company. He also served as president and CEO of transient receptor potential ion channel company Hydra Biosciences, which had its assets purchased by Eli Lilly. Herndon was COO and president at immuno-oncology firm Agenus and filled multiple roles at biotechnology company Genzyme, including president of Genzyme Tissue Repair and VP of regulatory affairs.
Housman was most recently VP/head of access of outcomes and population health at Exact Sciences. She previously served as global head of the therapeutics business and SVP of corporate development at artificial intelligence firm Molecular Health. Housman also led the market access, pricing, and health economics and outcomes research group in Novartis' pharma/molecular diagnostics division. She has served in leadership positions at Charles River Laboratories, Genzyme Genetics, and Blue Cross Blue Shield of Massachusetts. In addition, Housman is the founder of Access Solutions Consulting, an access strategy advisory firm.